Cargando…

Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

BACKGROUND: Little is known regarding the efficacy of immune checkpoint inhibitors (ICI) in patients with advanced large-cell neuroendocrine lung carcinoma (aLCNEC). METHODS: 125 consecutive patients with aLCNEC were identified in the electronic databases of 4 participating cancer centers. The patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dudnik, Elizabeth, Kareff, Samuel, Moskovitz, Mor, Kim, Chul, Liu, Stephen V, Lobachov, Anastasiya, Gottfried, Teodor, Urban, Damien, Zer, Alona, Rotem, Ofer, Onn, Amir, Wollner, Mira, Bar, Jair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893659/ https://www.ncbi.nlm.nih.gov/pubmed/33597218 http://dx.doi.org/10.1136/jitc-2020-001999

Ejemplares similares

Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors
por: Dudnik, Elizabeth, et al.
Publicado: (2021)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
por: Gal, Omer, et al.
Publicado: (2020)

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade
por: Harel, Michal, et al.
Publicado: (2022)

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone
por: Saad, Akram, et al.
Publicado: (2022)

The Impact of Comprehensive Genomic Profiling (CGP) on the Decision-Making Process in the Treatment of ALK-Rearranged Advanced Non-Small Cell Lung Cancer (aNSCLC) After Failure of 2(nd)/3(rd)-Generation ALK Tyrosine Kinase Inhibitors (TKIs)
por: Raphael, Ari, et al.
Publicado: (2022)

Long term follow-up of EGFR mutated NSCLC cases
por: Rennert, Gad, et al.
Publicado: (2020)

Oxaliplatin-Induced Pulmonary Toxicity in Gastrointestinal Malignancies: Two Case Reports and Review of the Literature
por: Moskovitz, Mor, et al.
Publicado: (2015)

Self-reported sleep quality as prognostic for survival in lung cancer patients
por: Gottfried, Teodor, et al.
Publicado: (2020)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
por: Daher, Sameh, et al.
Publicado: (2021)

Checkpoint therapeutic target database (CKTTD): the first comprehensive database for checkpoint targets and their modulators in cancer immunotherapy
por: Zhang, Yixiao, et al.
Publicado: (2020)

Long-Term Survival of Patients with Metastatic Non-Small-Cell Lung Cancer over Five Decades
por: Bar, Jair, et al.
Publicado: (2021)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients
por: Magri, Valentina, et al.
Publicado: (2019)

Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer
por: Onn, Amir, et al.
Publicado: (2021)

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit
por: Haberman, Yael, et al.
Publicado: (2023)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

TIGIT is a key inhibitory checkpoint receptor in lymphoma
por: Godfrey, James, et al.
Publicado: (2023)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records
por: Beaufils, Mathilde, et al.
Publicado: (2023)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
por: Cautela, Jennifer, et al.
Publicado: (2020)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
por: Reid, Pankti, et al.
Publicado: (2021)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
por: Coustal, Cyrille, et al.
Publicado: (2023)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
por: Drobni, Zsofia Dora, et al.
Publicado: (2023)

Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
por: Sternschuss, Michal, et al.
Publicado: (2020)

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
por: Landman, Yosef, et al.
Publicado: (2021)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma
por: Ho, Won Jin, et al.
Publicado: (2020)

Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors
por: Kelleher, Thomas, et al.
Publicado: (2021)

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
por: Rogiers, Aljosja, et al.
Publicado: (2021)

Oral beclomethasone dipropionate is an effective treatment for immune checkpoint inhibitor induced colitis
por: Alexander, James L, et al.
Publicado: (2022)

Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
por: Küçükköse, Emre, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p5ap5vjkcdnol11vobmd4dis90